Who
Sandesh Seth
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Actinium Pharmaceuticals, Inc. (Delaware); Director, Relmada Therapeutics.
In numbers
- Trades disclosed
- 61
- Buys
- 12
- Sells
- 0
- Bought
- $148K
- Sold
- $0
- Companies
- 2
- Companies where not an officer
- 1
- First trade
- 25 Jul 2013
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —753,600 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —1,027,274 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —1,130,400 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —1,130,400 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —753,600 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —1,027,274 at $0.00 | filing |
| 18 Aug 2025filed 20 Aug 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code F | $207K120,900 at $1.71 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —16,666 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —25,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —33,333 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —139,062 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —310,182 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —827,366 at $0.00 | filing |
| 31 Mar 2025filed 2 Apr 2025 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code D | —984,367 at $0.00 | filing |
| 28 Dec 2023filed 29 Dec 2023 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —984,367 at $0.00 | filing |
| 17 Aug 2022filed 19 Aug 2022 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)Biotechnology | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 1 Jul 2022filed 1 Jul 2022 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —827,366 at $0.00 | filing |
| 1 Sep 2021filed 3 Sep 2021 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —310,182 at $0.00 | filing |
| 12 Aug 2020filed 14 Aug 2020 | ATNM Actinium Pharmaceuticals, Inc. (Delaware)option or derivative · Biotechnology | SEC FORM 4 Code A | —139,062 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.